AAP
CHRS icon

Arax Advisory Partners’s Coherus Oncology CHRS Stock Holding History

Arax Advisory Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6K Buy
14,024
+13,791
+5,919% +$22.5K ﹤0.01% 3972
2026
Q1 		$394 Buy
233
+211
+959% +$375 ﹤0.01% 3454
2025
Q4 		$31 Sell
22
-7,289
-100% -$10.6K ﹤0.01% 3991
2025
Q3 		$12K Buy
+7,311
New +$8.13K ﹤0.01% 2513

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Arax Advisory Partners's CHRS Position: Q2 2026 in Review

Arax Advisory Partners increased its Coherus Oncology (CHRS) stake by 5,919% in Q2 2026, buying an estimated $22.5K and bringing the position to 14,024 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3972.

Arax Advisory Partners first reported a position in CHRS in Q3 2025 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Arax Advisory Partners held 14,024 shares of Coherus Oncology worth $19.6K as of Q2 2026.
  • Arax Advisory Partners bought 13,791 Coherus Oncology shares in Q2 2026, an estimated $22.5K.
  • Coherus Oncology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3972 holding.
  • Arax Advisory Partners first reported a position in Coherus Oncology in Q3 2025 and has held it in 4 quarters since.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.